tailieunhanh - Báo cáo toán học: " Ethical Perspectives on RNA Interference Therapeutics"

Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: Ethical Perspectives on RNA Interference Therapeutics. | Int. J. Med. Sci. 2008 5 159 Research Paper International Journal of Medical Sciences ISSN 1449-1907 2008 5 3 159-168 Ivyspring International Publisher. All rights reserved Ethical Perspectives on RNA Interference Therapeutics Mette Ebbesen1 2- 3 Thomas G. Jensen2 4 Svend Andersen1 and Finn Skou Pedersen3 5 1. Centre for Bioethics and Nanoethics University of Aarhus Denmark 2. Faculty of Health Sciences University of Aarhus Denmark 3. Interdisciplinary Nanoscience Center iNANO University of Aarhus Denmark 4. Institute of Human Genetics University of Aarhus Denmark 5. Department of Molecular Biology University of Aarhus Denmark Correspondence to Mette Ebbesen Centre for Bioethics and Nanoethics University of Aarhus Build. 1443 Taasingegade 3 DK-8000 Aarhus C Denmark. E-mail meb@ Phone 45 8942 2312 Received Accepted Published RNA interference is a mechanism for controlling normal gene expression which has recently begun to be employed as a potential therapeutic agent for a wide range of disorders including cancer infectious diseases and metabolic disorders. Clinical trials with RNA interference have begun. However challenges such as off-target effects toxicity and safe delivery methods have to be overcome before RNA interference can be considered as a conventional drug. So if RNA interference is to be used therapeutically we should perform a risk-benefit analysis. It is ethically relevant to perform a risk-benefit analysis since ethical obligations about not inflicting harm and promoting good are generally accepted. But the ethical issues in RNA interference therapeutics not only include a risk-benefit analysis but also considerations about respecting the autonomy of the patient and considerations about justice with regard to the inclusion criteria for participation in clinical trials and health care allocation. RNA interference is considered a new and promising therapeutic approach but the ethical issues of .